Gelsis (Boston, MA) is developing a breakthrough treatment for obesity and other gastrointestinal disorders has closed a $16M Series A. Participants include OrbiMed, Queensland BioCapital Funds, PureTech Ventures, Lansing Brown Investments and the Cape Family Fund.